Cardiac remodeling and pumping measurements are related but not interchangeable. This trial reported a difference in one without demonstrating a corresponding difference in the other. Primary study
What was observed
The randomized, double-blind CEDIM trial included 472 patients after acute anterior myocardial infarction. L-carnitine attenuated increases in left-ventricular volumes during follow-up. Changes in ejection fraction were not significantly different, and the trial did not demonstrate significant clinical-event differences. Primary report
Our appraisal: name the imaging endpoint accurately
Smaller ventricular volumes can be a meaningful remodeling observation, but they should not be paraphrased as a proven increase in ejection fraction when that comparison was neutral. The actual measured quantity belongs in the headline and conclusion.
Clinical outcomes require their own evidence. A trial designed around imaging may be insufficiently precise for mortality or heart-failure comparisons. A numerically favorable event count is not a demonstrated clinical benefit merely because it points in the same direction as an imaging result.
Eligibility based on high-quality imaging can also affect the population represented. Full review should examine who could not contribute suitable scans and how missing serial measurements were handled.
This study should be distinguished from CEDIM 2 and from later publications that summarize the original trial. Multiple reports of one cohort do not create multiple independent randomized studies. The later clinical-endpoint trial asks a related but different question.
The original report contributes an imaging-based remodeling signal in a historical treatment setting. It does not establish improved survival, greater exercise capacity, or a present-day treatment recommendation. Publication review should keep ventricular volumes, ejection fraction, and clinical events separate while checking scan analysis, follow-up completeness, and the prespecified statistical plan.
Frequently asked questions
How many patients were included?
Four hundred and seventy-two.
Did ventricular dilation differ?
The L-carnitine group showed less dilation.
Did ejection-fraction changes significantly differ?
No.
Were significant clinical-event benefits established?
No.
Is this the same trial as CEDIM 2?
No.
Can multiple reports of one cohort count as independent trials?
No.
What is the central distinction?
An imaging remodeling effect is not automatically a functional or survival benefit.